A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Inclusion Criteria: * Male or female, 18 to 75 years of age * Written informed consent * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * No new abnormal finding of clinical relevance at the screening evaluation. * Diagnosis of HBeAg negative, immune active, chronic HBV infection * \> 2 months of continuous treatment with daily, oral entecavir or tenofovir * Willingness to continue taking entecavir or tenofovir throughout the study. * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners) Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection within 4 weeks of screening * Antiviral therapy other than entecavir or tenofovir within 3 months of screening * Prior treatment with interferon in the last 3 years. * Use within the last 6 months or anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants. * Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, or hormonal contraceptives. * Depot injection or implant of any drug within 3 months prior to treatment administration, except injectable/implantable birth control. * Diagnosis of diabetes mellitus. * History of autoimmune disease especially autoimmune hepatitis. * Human immunodeficiency virus (HIV) infection. * Sero-positive for Hepatitis C Virus (HCV), and/or a history of delta virus hepatitis. * Hypertension defined as blood pressure \> 150/100 mmHg * History of cardiac rhythm disturbances * Family history or congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death * Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease within 6 months prior to study entry. * History of malignancy except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. * Has had a major surgery within 3 months of screening. * History of alcohol and/or drug abuse \< 12 months from screening. * Regular uses of alcohol within 6 months prior to screening (ie, more than 14 units of alcohol per week). * Evidence of severe systemic acute inflammation, sepsis, or hemolysis. * Diagnosed with a significant psychiatric disorder. * Use of recreational drugs, such as marijuana, within 3 months prior to screening * Use of drugs such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year prior to screening. * History of allergy to bee sting. * Use of investigational agents or devices within 30 days prior to planned study dosing or current participation in an investigational study. * Clinically significant history or presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease. * Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction. * Clinically significant history or presence of poorly controlled/uncontrolled systemic disease. * History of fever within 2 weeks of screening. * Immunized with a live attenuated vaccine within 7 days prior to dosing or planned vaccination (excluding flu vaccine by injection). * Presence of any medical or psychiatric condition or social situation that impacts compliance or results in additional safety risk. * Participated in excessive exercise/physical activity within 7 days of screening or planned during the trial. * History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant medication(s).